Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology by Crescioli, Silvia et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jaci.2017.12.986
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Crescioli, S., Chiaruttini, G., Mele, S., Ilieva, K. M., Pellizzari, G., Spencer, D. I. R., ... Karagiannis, S. N. (2018).
Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. Journal
of Allergy and Clinical Immunology. DOI: 10.1016/j.jaci.2017.12.986
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 28. Feb. 2018
Accepted Manuscript
Engineering and stable production of recombinant IgE for cancer immunotherapy and
AllergoOncology
Silvia Crescioli, PhD, Giulia Chiaruttini, PhD, Silvia Mele, PhD, Kristina M. Ilieva,
MRes, Giulia Pellizzari, MSc, Daniel I.R. Spencer, PhD, Richard A. Gardner, PhD,
Katie E. Lacy, MD PhD, James F. Spicer, MD PhD, Andrew N.J. Tutt, PhD, Gerd K.
Wagner, PhD, Sophia N. Karagiannis, PhD
PII: S0091-6749(18)30081-2
DOI: 10.1016/j.jaci.2017.12.986
Reference: YMAI 13225
To appear in: Journal of Allergy and Clinical Immunology
Received Date: 22 July 2017
Revised Date: 9 December 2017
Accepted Date: 18 December 2017
Please cite this article as: Crescioli S, Chiaruttini G, Mele S, Ilieva KM, Pellizzari G, Spencer DIR,
Gardner RA, Lacy KE, Spicer JF, Tutt ANJ, Wagner GK, Karagiannis SN, Engineering and stable
production of recombinant IgE for cancer immunotherapy and AllergoOncology, Journal of Allergy and
Clinical Immunology (2018), doi: 10.1016/j.jaci.2017.12.986.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1 
Engineering and stable production of recombinant IgE for cancer 
immunotherapy and AllergoOncology 
 
Silvia Crescioli PhD1,2*, Giulia Chiaruttini PhD1*, Silvia Mele PhD1, Kristina M. 
Ilieva MRes 1,3 Giulia Pellizzari MSc1, Daniel I. R. Spencer PhD4, Richard A. 
Gardner PhD4, Katie E. Lacy MD PhD1, James F. Spicer MD PhD5, Andrew N. J. 
Tutt PhD3,6, Gerd K. Wagner PhD6, Sophia N. Karagiannis PhD1,2,3 
 
1
 St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College 
London, 9th Floor, Tower Wing, Guy’s Hospital, London, SE1 9RT, United Kingdom 
2
 NIHR Biomedical Research Centre at Guy’s and St. Thomas’s Hospitals and King’s College 
London, King’s College London, London, SE1 9RT, United Kingdom 
3
 Breast Cancer Now Unit, School of Cancer & Pharmaceutical Sciences, King`s College 
London, Guy`s Cancer Centre, London SE1 9RT, United Kingdom 
4 Ludger Ltd, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom 
5 School of Cancer & Pharmaceutical Sciences, King`s College London, Guy`s Hospital, 
Bermondsey Wing, Floor 3, SE1 9RT, London, United Kingdom 
6 Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, 
United Kingdom 
7 King’s College London, Department of Chemistry, Faculty of Natural & Mathematical 
Sciences, Britannia House, 7 Trinity Street, London SE1 1DB, United Kingdom 
 
* These authors contributed equally to this work 
 
Corresponding Author: 
Sophia N. Karagiannis, PhD, St. John’s Institute of Dermatology, School of Basic & 
Medical Biosciences, King's College London, Guy’s Hospital, 9th Floor, Tower 
Wing, London, SE1 9RT, United Kingdom  
E-mail: sophia.karagiannis@kcl.ac.uk 
Tel:  +44(0)20 7188 6355 
Fax: +44(0)20 7188 8050 
 
Acknowledgements 
The research was supported by the National Institute for Health Research (NIHR) 
BRC based at Guy's and St Thomas' NHS Foundation Trust and King's College 
London (IS-BRC-1215-20006). The views expressed are those of the author(s) and 
not necessarily those of the NHS, the NIHR or the Department of Health. The authors 
acknowledge support by the Medical Research Council (MR/L023091/1); Breast 
Cancer Now (147), working in partnership with Walk the Walk; The British Skin 
Foundation (S633); The Dermatrust; Guy’s and St Thomas’s Charity Melanoma 
Special Fund; Cancer Research UK (C30122/A11527; C30122/A157745); the 
Academy of Medical Sciences; CR UK/EPSRC/MRC/NIHR KCL/UCL 
Comprehensive Cancer Imaging Centre (C1519/A10331); CR UK/NIHR in 
England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer 
Medicine Centre (C10355/A15587); BBSRC IBCarb Network (Proof-of-Concept 
award IBCarb-PoC-0616-040). We acknowledge the Biomedical Research Centre 
Immune Monitoring Core Facility team at Guy's and St Thomas' NHS Foundation 
Trust for assistance.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2 
Capsule summary 
We developed a versatile, novel, time- and resource-effective tool for production of 
functional IgE at high yields that has wide application potential in basic research and 
clinical evaluations in allergy, cancer immunotherapy and AllergoOncology.  
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AllergoOncology; IgE; cancer immunotherapy; effector cells; degranulation; antibody 
engineering 
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Engineering and stable production of recombinant IgE for cancer 
immunotherapy and AllergoOncology 
 
To the Editor:  
AllergoOncology, the emerging discipline of cancer immunology aiming to exploit 
features of allergy-related immunity to treat tumors (1–3), has catalyzed the 
development of tumor-specific IgE monoclonal antibodies as powerful alternatives to 
commonly-used therapeutic IgGs (4–6). IgE typically associated with the 
pathogenesis of allergic responses and known for Fc-mediated protective effects in 
parasitic infection clearance, presents exciting opportunities to unleash previously-
untapped immune mechanisms and effective anti-tumor surveillance when focused 
against cancer antigens. Anti-tumor efficacy of IgE has been demonstrated by 
numerous studies (1–3) and an early clinical trial of the first-in-class anti-tumor IgE in 
oncology is open (NCT02546921, www.clinicaltrials.gov). A major impediment in 
the field relates to lack of efficient cloning and production strategies for recombinant 
IgE at high-enough yields for pre-clinical and clinical studies.  
We aimed to develop a stable expression application to generate recombinant IgE, 
exemplified with an antibody recognizing the melanoma-associated antigen 
chondroitin sulphate proteoglycan 4 (CSPG4). Our strategy incorporates seamless 
cloning, selection and fast antibody production at high yields (Fig. 1a). To prevent 
promoter silencing, we developed a novel dual-plasmid system containing Ubiquitous 
Chromatin Opening Elements (UCOE) sequences, located upstream of the transgene 
promoter (7). We isolated the coding sequences of anti-CSPG4 IgE heavy and light 
chains from a previously-described (pVITRO1-CSPG4 IgE/k) vector (4) (Fig. 1b) and 
cloned these into two UCOE-vectors (UCOE-CSPG4-HC(ε), UCOE-CSPG4-LC(κ)) 
(Fig. 1c), employing Polymerase Incomplete Primer Extension (PIPE) cloning. UCOE 
enables higher transfection efficiency and higher proportions of medium- and high-
expressing transfectomas than pVITRO1 (see Figure E1 in the Online Repository). 
Vectors were linearized before transfections to allow correct integration into the host 
genome, and transgene-expressing cells were selected. The choice of Expi293FTM as 
hosts was based on human-like glycosylation profiles, ability to grow in suspension, 
high-density and serum-free conditions, characteristics crucial for expediting 
production, scaling up and adaptability to good manufacturing practice (GMP) 
conditions. We adapted Expi293FTM cells from suspension to adherent growth 
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conditions and vice-versa. Adherent cells were transfected and seeded in selection 
medium to promote host genome integration of exogenous DNA. Resistant cells were 
cloned by limiting dilution. We designed a cell-based flow cytometric method to 
detect functional IgE recognizing natively-expressed antigens to screen antibody-
secreting clones (see Figure E1 in the Online Repository). High antibody-expressing 
clones were amplified and re-adapted to grow in high-density suspension cultures for 
antibody harvesting. 
After selecting the highest-expressing clone, we optimized culture conditions to 
maximize IgE production and minimize time and resources. We observed a slow 
decrease of specific daily antibody productivity, consistent with cell growth rate and 
consumption of culture medium nutrients. This productivity decrease was due to 
nutrient depletion in the medium rather than cell density (see Figure E2 in the Online 
Repository). To maximize yields, we tested different seeding Expi-CSPG4 IgE cell 
concentrations in fresh medium, measuring secreted antibody daily for 5 days. As 
expected, higher starting cell concentration yielded faster and higher antibody 
production, with cells seeded at 11x106 cells/mL generating 2mg/day (Fig. 1d).  
Using high cell concentrations (5x106 and 11x106 cells/mL), that place cells under 
stress, we analysed production consistency over time by passaging every two days at 
5x106 (5M/mL 2D), or every day at 5x106 (5M/mL 1D) or 11x106 cells/mL (11M/mL 
1D), replacing media at every passage. After 4 days all conditions yielded consistent 
antibody production (Fig. 1e). The 11M/mL 1D and 5M/mL 2D conditions yielded 
similar production per passage. However, 11M/mL 1D resulted in the highest 
production per day (see Figure E3 in the Online Repository), suggesting this is 
optimal for reducing resources and time. 
IgE production reached yields of up to 87mg/L/day (83±4 mg/L/day mean±SD), with 
ability to repeat the process with the same cells at least 3 times without losing 
production efficiency. Yields in 4 days, in small shaking flask cultures, were 
approximately 33-fold higher than the most optimal 14-day stable IgE production 
recorded in shaking flask conditions, and 13-fold higher than 14-day IgE production 
reported using bioreactors (4). Optimized high-density conditions allowed maximized 
yields and substantially-reduced medium volumes, achieving 2mg/25mL/day, with 
similar yields scaling down to 15mL and up to 300mL cultures.  
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Different culture conditions can affect antibody quality, structural and functional 
properties, including post-translational modifications such as glycosylation (8). This 
is highly pertinent for IgE, based on larger size and higher glycosylation levels 
compared with IgG. We performed structural, glycosylation and functional analyses 
comparing affinity chromatography-purified antibodies from high- and low-density 
cultures alongside IgE produced with the previous pVITRO method (4).  
Size-exclusion High Pressure Liquid Chromatography (HPLC), showed very similar 
antibody main peak profiles (Fig. 2a). Lectin blot and LC-MS glycosylation analyses, 
revealed no significant differences among IgE produced with our method (Fig. 2b, 
2c), particularly with regards to oligomannose structures, whose removal is reported 
to abrogate anaphylaxis (9). LC-MS glycosylation analyses showed a reduction in 
MAN5 oligomannose structure in new preparations compared to pVITRO IgE. 
Antibodies from all conditions showed comparable binding characteristics to target 
antigen on A375 melanoma cells and to rat basophilic leukemia RBL-SX38 cells 
expressing human FcεRI (Fig. 2d). All preparations triggered significant and 
comparable levels of mast cell degranulation when cross-linked by polyclonal anti-
IgE or by target antigen on CSPG4high melanoma cells (Fig. 2e). The hapten-specific 
NIP-IgE cross-linked by polyclonal anti-IgE, but not by CSPG4high cells, triggered 
significant degranulation. These suggest that different preparations and density 
conditions preserve receptor recognition and antibody potency. Importantly, reduced 
MAN5 in the new IgE is insufficient to impact IgE binding or functionality.  
We therefore present a novel process for serum-free production of IgE with 
comparable structural and functional characteristics to previous pVITRO method, but 
at higher yield and in less time than any documented stable platforms and with less 
resources than transient systems (see Table E1 in the Online Repository). This offers 
new opportunities to expedite the design of novel therapeutic antibodies with 
enhanced effector functions, suitable for basic and translational research, scale up, 
process development and manufacturing for clinical trials of IgE therapy in cancer. 
Rapid generation of IgE antibodies recognizing allergens, cancer antigens or parasitic 
targets can find direct applications for exploring multifaceted functions of IgE in 
Allergy, Oncology and AllergoOncology.  
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Figure Legends 
 
Figure 1. Development of a stable platform for the expression of recombinant 
IgE (a) Flow chart summarising the development of stable cell lines expressing anti-
CSPG4 IgE. (b) pVITRO1-CSPG4-IgE/κ vector and (c) UCOE-CSPG4-HC(ɛ) and 
UCOE-CSPG4-LC(κ) vectors maps. To optimize antibody production Expi-CSPG4-
IgE cells were cultured in different conditions and IgE secretion and cell viability 
were monitored daily. (d) Secreted IgE in cultures seeded at 0.5, 2, 5 or 11x106 
cells/mL in fresh medium. (e) Secreted IgE in cultures seeded at 5x106 or 11x106 
cells/mL in 25 mL fresh medium and re-seeded at the initial concentration every day 
(5M/mL 1D, 11M/mL 1D) or every two days (5M/mL 2D). (d, e) Data represent 
mean ± SEM of four independent experiments. 
 
Figure 2. Structural and functional characterization of IgE produced under 
different conditions. IgEs were purified from supernatant of Freestyle293F-CSPG4 
IgE (pVITRO) or Expi-CSPG4 IgE cultured at 0.5x106 for 4 days, (0.5M/mL 4D), 
5x106 for 2 days (5M/mL 2D), 5x106 for 1 day (5M/mL 1D) or 11x106 cells/mL for 1 
day (11M/mL 1D). Structural characterization was performed by (a) HPLC; (b) 
Lectin blot using Con-A, AAL, and RCAI. Images show one representative 
experiment. Graphs show densitometric analyses normalized by kappa light chain 
western blot. Data represent mean ± SEM of two independent experiments. (c) LC-
MS glycosylation analysis, graph represents the relative % areas for each UHPLC 
chromatograms peak of procainamide labelled N-glycan released from each sample. 
Data represent mean ± SD. Monosaccharide compositions assigned to peaks: 
H=hexose, N=N-acetylhexosamine, F=fucose, S=sialic acid; Possible N-glycan 
structures shown in brackets: F=Fucose, A=antenna, G=galactose, MAN=mannose, 
S=sialic acid. (d) IgE binding kinetics to CSPG4 antigen (A375 cells) and FcεRI 
(RBL-SX38 cells). (e) IgE mediated degranulation of RBL-SX38 mast cells, 
measured in: negative control (no cross-linker), positive control (polyclonal anti-IgE), 
and using a CSPG4-expressing tumour cell line to trigger cross-linking of anti-CSPG4 
IgE-FcεRI complexes. Data represent mean ± SEM of four independent experiments 
(ns = not significant, ** = P<0.01, **** = P<0.0001).   
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Materials and Methods 
 
Cell lines  
Expi293FTM were cultured in Expi293TM Expression Medium in suspension and 
shaking conditions (125rpm) at 37°C and 8% CO2 according to the manufacturer’s 
instructions, seeding them at 0.5x106 cells/mL every 4 days. A375 melanoma cells 
were cultured in adhesion in Dulbecco’s modified Eagle’s medium (DMEM) high 
glucose supplemented with GlutaMAXTM (Gibco) and 10% Fetal Bovine Serum 
(FBS). RBL-SX38 rat basophilic leukemia cells (engineered to express the human 
FcεRI) (1) were cultured in adhesion.  
 
CSPG4 IgE expression vectors  
The pVITRO1-CSPG4-IgE/k vector (Fig 1b) was previously developed in our group  
(2). The dual UCOE-vector system (UCOE-CSPG4-HC(ɛ) and UCOE-CSPG4-
LC(κ)) (Fig 1c) was developed by Polymerase Incomplete Primer Extension (PIPE) 
cloning as described before (2). Briefly, the coding sequence of CSPG4 IgE heavy 
and light chains were isolated from pVITRO1-CSPG4-IgE/k vector and UCOE® Mu-
H vector (Merck Millipore) was linearized in three portions by using the primers in 
Table E2 and the PCR conditions reported in Table E3 in the Online Repository. The 
PCR products were then digested for 2 hours at 37°C with DpnI (NEB) to eliminate 
template DNA, and two separate mixes were prepared using the three vector portions 
and one heavy or light chain. The two mixes were incubated overnight at room 
temperature and then used to transform chemically competent One ShotTM Top10 
bacteria (Invitrogen) according to the manufacturer’s instruction.  
 
Development of stable IgE expressing Expi293FTM cells 
The Expi293FTM cell line (Gibco) was cultured according to the manufacturer’s 
instructions in Expi293TM Expression Medium (Gibco). One day before transfection, 
2x105 cells were seeded in a 24-well plate in DMEM high glucose supplemented with 
GlutaMAXTM (Gibco) and 10% FBS in order to simultaneously adapt them to grow in 
adherence conditions and achieve 90% confluence at the point of transfection. UCOE-
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CSPG4-HC(ε) and UCOE-CSPG4-LC(k) were linearized using I-SceI (NEB) 
according to the manufacturer’s instruction. Adherent cells were transfected with 
either pVITRO1-CSPG4-IgE/k or the two linearized UCOE-vectors, using 0.8µg of 
DNA, 2µL of Lipofectamine® 2000 (Invitrogen) and 600µL of Opti-MEM® I 
Reduced Serum Medium (Gibco) according to the manufacturer’s instructions. A 
mock transfection (without vector) was performed as control. Sixteen hours after the 
transfection the cells were split 1:10 and seeded in complete medium (DMEM-high 
glucose supplemented with GlutaMAXTM (Gibco) and 10% FBS). The following day 
media were replaced with selection medium (complete medium supplemented with 
200µg/mL Hygromycin B (Sigma)). Cells were then cultured replacing the selective 
medium every 3 days until the point when all the cells from the mock transfection 
died. The selection-resistant cells were then amplified and cloned by limiting dilution 
in selection media. After 2 weeks, the clones were screened for the secretion of anti-
CSPG4 IgE in the supernatant, positive clones were amplified and then adapted back 
to growth in suspension and shaking conditions in Expi293TM Expression Medium. 
Different clones were frozen and the best clone (Expi-CSPG4 IgE) was used for the 
optimization of antibody production.  
 
CSPG4 IgE production with stable Freestyle293-CSPG4 IgE cells 
CSPG4 IgE was produced culturing Freestyle293-CSPG4 IgE according to our 
previously described method (pVITRO1)(2).  
 
ELISA assay for the detection and quantification of IgE in cell supernatants  
To quantify anti-CSPG4 IgE in cell culture supernatants, 96-well plates were coated 
overnight at 4°C with 10µg/mL of polyclonal rabbit anti-IgE (Dako) in 0.2M 
carbonate-bicarbonate buffer, pH 9.4. Plates were incubated in blocking buffer 
(Phosphate buffered saline (PBS) (0.01M phosphate buffer, 0.0027M KCl, 0.14M 
NaCl) pH 7.4 supplemented with 1% BSA) for 1 hour at room temperature, washed 3 
times with washing buffer (PBS+0.05% Tween-20) and incubated with supernatants 
or with the IgE antibody standard at different dilutions for 2 hour at room 
temperature. All conditions were tested in duplicate. Plates were washed 3 times and 
incubated with 10µg/mL goat anti-human Fcɛ-HRP (Sigma-Aldrich) in blocking 
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buffer for 1.5 hours at room temperature. Following 3 washes, samples were treated 
with 50µL of 0.5mg/mL o-phenylenediaminedihydrochloride substrate (Sigma-
Aldrich) in peroxide substrate buffer (Pierce) for 5 minutes at room temperature. 
Following addition of 50µL per well Stop Solution (1M HCl), plates were read at 
492nm (reference wavelength 540nm) on a Fluostar Omega microplate reader (BMG 
Labtech).  
 
Flow cytometry-based assay for the detection and quantification of antigen-
specific IgEs in cell supernatants  
This method is based on the detection, in cell supernatants, of IgE antibodies that 
specifically bind to CSPG4high tumor (A375 melanoma) cells. A375 cells were 
detached using PBS supplemented with 5mM EDTA and resuspended in PBS 
supplemented with 2% FBS (FACS buffer). For this assay were used 105 cells per 
sample in a final volume of 100 µL. For the quantification of antigen-specific IgE a 
standard curve was prepared using 1:2 serial dilutions of CSPG4 IgE. For the analysis 
of CSPG4 IgE in cell culture supernatants, 0.1µL of supernatant was prepared FACS 
buffer, for a final dilution of 1:1,000. Primary antibodies were incubated 30 minutes 
at 4 °C followed by a wash with 3 mL of FACS buffer (spinning at 500g for 5 
minutes). The secondary antibody goat anti-human IgE FITC (FI-3040, Vector 
Laboratories) was incubated at 30µg/mL in FACS buffer for 30 minutes at 4 °C 
followed by one wash as above. Samples were resuspended in 100µL of FACS buffer 
and analysed using a FACS Canto II (BD Biosciences). 
 
Purification of CSPG4 IgE 
CPSG4 IgE was purified using HiTrap KappaSelect columns (GE Healthcare) 
according to the manufacturer’s instructions. Briefly, columns were equilibrated with 
10 column volumes (cv) of PBS, cell culture supernatant was diluted 1:1 v/v with 
PBS and samples were loaded on the column followed by a wash using at least 20 cv 
of PBS. The sample was then eluted with 5 cv of 0.1M glycine buffer, pH 2.3 and 
immediately buffered to pH 7.5 using 1 M Tris, pH 9.0. Purified antibodies were then 
dialyzed against PBS overnight at 4 °C and sterilized using a 0.2µm sterile filter. 
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Size exclusion chromatography 
Purified antibodies were analysed by size exclusion chromatography as previously 
described (3). Briefly, gel filtration was performed on a Gilson HPLC system using a 
SuperdexTM 200 10/300 GL column (GE Healthcare), suitable for purifying proteins 
between 10–300 kDa, at a flow rate of 0.75 mL/min in PBS (pH 7.0, 0.2µm filtered). 
 
Lectin blot 
Purified IgE samples (150ng) were reduced with 50 mM DTT and boiled at 95 °C for 
5 minutes. The samples were run at 150V on Mini-PROTEAN TGX Gels 4–15% 
(Bio-Rad) and blotted with Trans-Blot® Turbo™ Transfer Pack PVDF (Bio-Rad) 
using Trans-Blot® Turbo™ Blotting System (Bio-Rad) according to manufacturer’s 
instruction. The blotted membrane was then cut just above 35kDa in order to have 
heavy (50kDa) and light (25kDa) chain in different membranes. The heavy chain 
membrane was blocked with Carbo-Free™ Blocking Solution (Vectorlab) for 1 hour 
and then probed with RCAI-biotin (Ricinus Cummunis Agglutinin I lectin (Vectorlab) 
specific for Galactose), or AAL-biotin (Aleuria Aurantia lectin (Vectorlab) specific 
for Fucose), or Con A-biotin (Concavalin A lectin (Vectorlab) specific for Mannose), 
0.2µg/mL in Carbo-Free™ Blocking Solution for 30 minutes. The membrane was 
then washed three times in PBS-Tween 0.05% (T-PBS) and incubated with High 
Sensitivity HRP-streptavidin (Pierce) (1:30,000) for 30 minutes, washed as above and 
developed with ECL (Amersham, GE Healthcare). The light chain membrane was 
blocked with T-PBS 5% BSA for 1 hour at room temperature and then incubated 
overnight at 4°C with rabbit anti-human-kappa light chain antibody (Abcam) (1:1,000 
in T-PBS 5% BSA) followed by three washes in T-PBS. The membrane was 
incubated with anti-rabbit-IgG HRP antibody (Cell Signaling Technology) (1:2,000 in 
T-PBS 5% BSA) for 1 hour at room temperature, washed as above and developed 
with ECL. Densitometric quantification was performed with ImageJ software, values 
were normalized by the loading control (kappa light chain) and for the value obtained 
in 0.5M/mL 4D culture condition.  
 
PNGase F release of N-glycans 
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IgE samples weredried down prior to releaseThe PNGase F release of N-glycans (E-
PNG01, QABio) was performed in a similar manner to that previously published (4). 
In short, 25 µg aliquots of the samples in water (17.5 µL) were incubated with 5 µL of 
5x Reaction Buffer 7.5 and 1.25 µL of Denaturation Solution for 10 minutes at 100°C 
followed by the addition of Triton X-100(1.25 µL) and PNGase F solution (1 µL) and 
incubation overnight at 37°C. Dried-down samples were treated with 20 µL of 1% 
formic acid for 50 minutes at RT followed by removal of protein material using a 
Protein Binding Membrane (PBM) plate (LC-PBM-96, Ludger Ltd).  
 
Procainamide labeling and cleanup 
Released glycans were labelled with procainamide using a procainamide labelling kit 
(LT-KPROC-24, Ludger Ltd) in a similar manner to that previously reported (5). In 
short, 150 µL of 30% glacial acetic acid in DMSO was added to a vial of 
procainamide followed by 150 µL of water. This solution was transferred to a vial of 
sodium cyanoborohydride to make the final labelling reagent. 20 µL of labeling 
reagent was added to each sample. The samples were then incubated for 1 hour at 
65°C. A HILIC method was performed to clean up the samples and remove free dye 
using an LC-PROC-96 plate (Ludger Ltd) on a vacuum manifold. Samples were 
eluted from the cleanup plate in 300 µL of water.  
 
LC-MS analysis of procainamide labeled N-glycans 
Samples were analysed by HILIC-LC on an Ultimate 3000 UHPLC using a BEH-
Glycan 1.7µm, 2.1x150mm column (Waters) at 40°C with a fluorescence detector 
(λex = 310nm, λem = 370nm), controlled by Bruker HyStar 3.2 (Bruker). Buffer A 
was 50mM ammonium formate made from LudgerSep N Buffer stock solution, pH 
4.4 [LS-N-BUFFX40]; buffer B was acetonitrile (acetonitrile 190 far UV/gradient 
quality; Romil #H049). Samples were injected in 25% aqueous/75% acetonitrile; 
injection volume 25 µL. The separation was performed using a linear gradient of 76-
53% ACN at 0.4mL/min in a 71 minute analytical run. PROC labelled glucose 
homopolymer was used as a system suitability standard as well as an external 
calibration standard for GU allocation for the system. Chromeleon data software 
version 7.2 (Thermo) with a cubic spline fit was used to allocate glucose unit (GU) 
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values to peaks. A Bruker amaZon Speed ETD electrospray mass spectrometer 
(Bruker) was coupled directly after the UHPLC FD without splitting. The instrument 
scanned samples in maximum resolution mode, positive ion setting, MS scan + three 
MS/MS scans, nebuliser pressure 14.5 psi, nitrogen flow 10L/min, capillary voltage 
4500 Volts. MS/MS was performed on three ions in each scan sweep with a mixing 
time of 40 ms. Mass spectrometry data were analysed using the Bruker Compass 
DataAnalysis 4.1 software. 
 
Binding of CSPG4 IgE to tumor and immune cell lines 
Binding of CSPG4 IgE to A375 and RBL SX38 cells was performed using 105 cells 
per sample. Cells were detached using PBS + 5mM EDTA. For each primary 
antibody, serial dilutions were prepared in FACS buffer (PB , 2% FBS). Primary 
antibodies were incubated for 30 minutes at 4°C followed by a wash with 3 mL of 
FACS buffer (spinning at 500g for 5 minutes). Samples were incubated with 
secondary antibody goat anti-human IgE FITC (FI-3040, Vector Laboratories) at 30 
µg/mL in FACS buffer per sample for 30 minutes at 4°C followed by one wash as 
above. Samples were resuspended in 100µL of FACS buffer and analysed using a 
FACS Canto II.  
 
Rat basophilic leukaemia SX-38 degranulation assays 
We evaluated degranulation of RBL-SX38 cells by quantifying b-hexosaminidase 
release, as previously described (6,7). Control conditions used were: unstimulated 
cells; Triton X-100 lysed cells (to quantify 100% granule release); chimeric NIP IgE 
against the hapten 5-iodo-4-hydroxy-3-nitrophenyl; Unstimulated or NIP IgE-
stimulated cells plus polyclonal rabbit anti-IgE (Dako) or antigen-expressing tumor 
cells as cross-linkers. Cells were seeded at 1x104 cells per well in culture medium 
overnight. The next day cells were sensitized with IgE (200ng/mL), control antibody 
or medium alone by incubating them at 37°C for 2 hours. Cells were then washed 3 
times in stimulation buffer (HBSS, 1% FBS; Gibco) and stimulated for 45 minutes at 
37°C with 100µL stimulation buffer, rabbit anti-IgE (1.5µg/mL), or 3x104 CSPG4high 
A375 tumour cell line. To detect β-hexosaminidase, 50µL culture supernatants diluted 
1:1 in stimulation buffer were transferred onto black 96-well plates with 50µL 
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florigenic substrate per well (1mM 4-methylumbelliferyl N-acetyl-b-D-
glucosaminide, 0.1% DMSO, 0.1% Triton X-100, 200mM citrate, pH 4.5) and 
incubated for 2 hours in the dark at 37°C. Reactions were quenched with 100µL per 
well 0.5 M Tris and plates read with a Fluostar Omega microplate reader (350 nm 
excitation, 450 nm emission) (BMG Labtech). Degranulation was expressed as a 
percentage of Triton X-100 release (100%), and compared with unstimulated cells 
(0%). 
 
Evaluation of antibody-specific productivity  
Expi-CSPG4-IgE cells were cultured in different conditions and IgE secretion and cell 
viability were monitored daily. Antibody-specific productivity qmAb (pg cell-1 day-1) 
was calculated according to the following equation (8):  
 =

 − 
 	× 	
log 
⁄ 
 
with mmAb being secreted IgE, N and N0 being the final and the initial viable cell 
values, respectively, and t being the days in culture.  
 
Statistical analysis 
Error bars represent the standard deviation (SD) or the standard error of the mean 
(SEM). The statistical significance of degranulation assay was calculated with one-
way ANOVA with Dunnett's multiple comparisons test. P values lower than 0.05 
were considered statistically significant, single, double, triple and quadruple asterisks 
indicate P < 0.05, P < 0.01, P < 0.001, P < 0.0001, respectively. Data were analyzed 
with Prism 7 software (GraphPad). 
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Table E1: Main features of the proposed method 
Expression host Expi293FTM (human origin, suitable for 
high density and serum free culture 
conditions) 
Vector Dual system with monocistronic UCOE-
vectors (strong CMV promoter for high 
expression, UCOE sequence able to 
prevent promoter silencing) 
Expression system Stable 
Vessel and physical conditions Shaking flasks (125 rpm), 37 °C, 8%CO2 
Medium Expi293TM Expression Medium, serum 
free 
Yield up to 87 mg/L 
Volume Suitable for small and upscaled cultures 
(from 15 to 300 mL) 
Cell density up to 11x106 cells/mL 
Time to setup the stable platform ~ 50 days 
Time for antibody expression 24 hours (2 mg in 25 ml culture) 
Cost for the setup of the stable 
platform 
PIPE cloning, adhesion based and small 
volume stable transfection with 
Lipofectamine® 2000 and FACS based 
screening of clones, make the development 
of the stable platform cost-effective 
compared to the production of antibody 
using transient transfections 
Cost for antibody expression High yield in a small volume of Expi293TM 
Expression Medium (up to 87 mg of IgE 
for 1 L of medium) 
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Table E2: PIPE cloning primers 
PRIMER NAME 5’-3’ SEQUENCE 
Isolation of ε heavy chain 
H F AGTTAACGGCCGGCCATGGACTGGACCTGGAGGA
TCCTC 
E R TGCAGCTCGAGTCATTTACCGGGATTTACAGACA
CCGCT 
Isolation of κ light chain 
K F AGTTAACGGCCGGCCATGTTGCCATCACAACTCA
TTGGG 
K R TGCAGGTCGACCTAACACTCTCCCCTGTTGAAGC
TC 
UCOE® vector linearization in 3 segments (U1, U2, U3) 
U1 F GTCGACCTGCAGGCATGCAAG 
U1 R CGTTGTCAGAAGTAAGTTGG 
U2 F CCAACTTACTTCTGACAACG 
U2 R AGCACTAACGAAGTAGAGGG 
U3 F CCCTCTACTTCGTTAGTGCT 
U3 R GGCCGGCCGTTAACTTAACTAAC 
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Table E3: PIPE cloning PCR conditions 
 
Temperature (°C) Time (s) 
ε heavy chain κ light Chain U1 U2 U3 
98 10 10 10 10 10 
98 1 1 1 1 1 
60 5 5 5 5 5 
72 23 9 43 42 34 
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Figure E1. Detection of functionally-active antibodies in culture supernatants by 
flow cytometry. (a) Schematic depicting the principle for antibody detection in cell 
culture supernatants by classical sandwich-ELISA (ELISA) and by our novel 
cytofluorimetric based assay (flow cytometry). (b,c) Standard curves showing the 
ranges of linearity (dotted lines) for the ELISA (b), and for the flow cytometry 
method (c). (d) Comparison between IgE concentrations calculated with ELISA and 
flow cytometry methods. Error bars represent s.e.m. of three independent 
experiments. (e) Screening of clones transfected with pVITRO1-vector or UCOE-
vector system graph representing secreted anti-CSPG4 IgE detected with the flow 
cytometry method. Clones secreting between 2 and 4 µg/mL of anti-CSPG4 IgE were 
considered medium expressing, and the ones that produced above 4 µg/mL were 
considered high expressing. Right panel summarizes absolute numbers and 
percentages of different expression levels of antibody.  
 
Figure E2. Culture medium conditions for optimal antibody production. To 
optimize antibody production Expi-CSPG4-IgE cells were cultured in different 
conditions and IgE secretion and cell viability were monitored daily.  (a) Secreted IgE 
and viable cells in cultures seeded at 0.5x106 cells/mL in fresh medium. (b) Antibody-
specific productivity calculated from (a). Graphs in (a,b) represent one of two 
independent experiments. (c) Secreted IgE (left panel) and viable cells (right panel) in 
cultures seeded at 5x106 cells/mL in fresh or metabolized medium. Secreted IgE are 
normalized on secreted IgE at day 0. Data represent mean ± SEM of four independent 
experiments.  
 
Figure E3. Analysis of the data reported in Figure 1e. Bar chart representing the 
average yield per passage (mg/L) (a), or the average yield per day (mg/day) (b). Data 
represent mean ± SEM of four independent experiments. 
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